Memantine in Systemic Lupus Erythematosus
Completed · Not applicable · Has a placebo group
Conditions studied: Systemic Lupus Erythematosus
In brief
Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor.
Key facts
- Study ID
- NCT00181298
- Run by
- Johns Hopkins University
- People needed
- 61
- Starts
- 2006-03-01
- Expected to finish
- 2007-05-01
- Last updated by the study team
- 2008-03-07
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Clinical diagnosis of SLE
- Self-reported cognitive impairment
You may not qualify if…
- Age < 18 years.
- History of non-compliance
- Pregnancy
- Liver or renal insufficiency/failure (calculated creatinine clearance < 50 cc/min)
- Severe SLE flare in the last 6 weeks (defined as SLEDAI > 12 points)
- Recent (within 4 weeks) change in any medication relevant to cognitive function, including prednisone, anti-depressants, medications for insomnia, narcotic medications, attention deficit disorder medications
- Current alcohol or illicit drug abuse
- Current use of Namenda, Aricept, Provigil
Where it is running
- Johns Hopkins Lupus Center, 1830 East Monument Street, Suite 7500 — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.